Highlights Q4 2024 and Q1 2025 with multiple potential liquidity events, growth in multiple subsidiaries as well as potentially significant reduction in overhead and expenses
Company to hold a virtual conference call Wednesday, November 13, 2024, at 11:00 AM ET
GARDEN CITY, NY, Nov. 13, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, and diagnostics company, today reported its financial and operational results for the three months ended September 30, 2024. The Company also highlighted substantial progress in its ongoing strategic initiatives, which are expected to drive significant revenue growth and potentially significant liquidity events in the upcoming quarters.
Key Highlights:
Pharmaloz Manufacturing projects $15+ million revenues and $5+ million pre-tax earnings over next 12 months not including potential contribution from second manufacturing line.
Developing a potential strategy before year-end to eliminate approximately $6 million per year in overhead and expenses in 2025 to focus on core assets and initiatives.
Company Initiates BE-Smart Esophageal Cancer Test Strategic Partnership Discussions
DNA Complete and DNA Expand successfully launch; Anticipates Strong Holiday Gift Giving Season
Equivir major clinical study results due shortly with anticipated launch around year-end.
Pharmaloz Manufacturing:
- Hired ThinkEquity investment bank to explore strategic alternatives including a potential sale of Pharmaloz Manufacturing.
- The Company estimates $15 million+ in revenues over the next 12 months starting in Q4 2024. This does not include any contribution from the planned second lozenge manufacturing line.
- In late-stage discussions with a major lozenge brand to enter a long-term contract to take over the entire capacity of the planned second lozenge manufacturing line. The Company estimates that this long term contract would add an additional $20-$25 million of revenues in its first full year of production and have the potential to grow further over time.
- Signed two top-tier lozenge brands, which we expect to add approximately $5million in annualized revenues with strong profit margins.
- Also, in discussions to add several additional lozenge brands.
- Starting in January 2025, a large new customer is expected to start production of a non-seasonal lozenge, improving off-season business.
- Lozenge manufacturing line #2 is built and is ready to be delivered.
- Lozenge line #3 planned for H2 2025, which would increase capacity significantly.
- The new lines are highly automated, include key dry feed systems, require less labor and are therefore expected to deliver both increased revenues and improved margins.
BE-Smart Esophageal Cancer Test:
- The Company has initiated strategic partnership discussions with two multi-billion-dollar cancer diagnostic testing companies in collaboration with Forward Healthcare Consultants (FHC).
- Also working with FHC to secure market access, insurance reimbursement and engage physician networks.
- Received additional samples from Mayo Clinic for expanded data analysis.
- Pursuing validation through additional studies and peer-reviewed publications.
DNA Complete and DNA Expand:
- Launched with a comprehensive marketing campaign led by industry experts.
- Offers advanced genetic analysis, competitive pricing, and faster turnaround times.
- Introduced subscription services, enhancing customer engagement and creating opportunities to generate high-margin revenue.
- Prioritizes data security with world-class cybersecurity measures.
Equivir Clinical Trial:
- Trial completed; final statistical analysis expected by end of November.
- Preliminary review of final data is encouraging, supporting key claims for future sales.
- Preparing a peer-reviewed paper detailing trial results, expected by end of Q4.
- Positioned as a pioneering, sugar-free supplement with clinical evidence supporting efficacy as both a therapeutic (shortening both duration and severity of symptoms) and as a prophylactic enhancing immunity against upper respiratory infections.
- Anticipating strong retail interest, leveraging the extensive marketing platforms of DNA Complete.
Financial Outlook:
ProPhase anticipates significant sequential improvement in revenues and EBITDA in Q4 2024, and beyond, driven by strategic advancements across its subsidiaries. The company remains financially strong, with $3.1 million in cash and cash equivalents as of November 12, 2024, and an improved working capital position from the quarter end.
CEO Commentary:
Ted Karkus, ProPhase Labs’ Chief Executive Officer, commented:
“Q3 2024 showcased the significant potential of our subsidiaries. Pharmaloz has a tremendous short-term and long-term outlook for growth and potential sale. BE-Smart has the potential to one day achieve a $1+ billion valuation. The probability of achieving this potential is further heightened by the collaboration with Forward Healthcare Consultants. This could include a significant partnership with a major cancer diagnostic testing company in the coming months. The successful launch of DNA Complete and DNA Expand is the result of dedicated efforts by our leadership and consultants, notably Jason Karkus and Stu Hollenshead, and we look forward to a strong holiday season. And the beauty of DNA Expand is that it will include a subscription and does not require additional lab sequencing. The margins on this initiative should be quite significant. And finally, Equivir is to follow just a couple of months after the launch of our DNA family of products. Given our historical success in building and selling the Cold-EEZE brand for $50 million, we believe that Equivir has even greater potential.
Our strategic moves position us well for substantial growth in Q4 2024 and beyond. Given the new growth and profitability at Pharmaloz, the recent launch of DNA Complete and DNA Expand, and the soon to launch Equivir, when combined with potential and significant reductions in overhead and expenses before year-end, our outlook for 2025 is exciting to say the least. As always, we remain focused on maximizing shareholder value through disciplined execution and strategic expansion.”
Third Quarter 2024 Financial Results
Three Months Ended September 30, 2024 as Compared to the Three Months Ended September 30, 2023
For the three months ended September 30, 2024, net revenue was $3.1 million as compared to $8.4 million for the three months ended September 30, 2023. The decrease in net revenue was the result of a $2.5 million decrease in net revenue from diagnostic services, and a $2.7 million decrease in consumer products. The decrease in net revenue for diagnostic services was due to decreased COVID-19 testing volumes compared to the 2023 period. Overall diagnostic testing volume decreased from 13,000 tests in the three months ended September 30, 2023 to zero tests in the three months ended September 30, 2024. None of the tests during the three months ended June 30, 2023 were reimbursed by the HRSA uninsured program.
Cost of revenues for the three months ended September 30, 2024 were $3.3 million, comprised of $0.5 million for diagnostic services and $2.8 million for consumer products. Cost of revenues for the three months ended September 30, 2023 were $6.0 million, comprised of $1.8 million for diagnostic services and $4.2 million for consumer products.
We realized a gross margin loss of $0.2 million for the three months ended September 30, 2024 as compared to a gross margin profit of $2.3 million for the three months ended September 30, 2023. The decrease of $2.5 million was comprised of a decrease of $1.2 million in diagnostic services, and a decrease of $1.3 million in consumer products. For the three months ended September 30, 2024 and 2023, we realized an overall gross margin of (5.2)% and 27.8%, respectively. Gross margin for diagnostic services was zero or not applicable due to no revenue and 27.8% in the 2024 and 2023 comparable periods, respectively. Gross margin for consumer products was 10.7% and 27.8% in the 2024 and 2023 comparable periods, respectively. Gross margin for consumer products have historically been influenced by fluctuations in quarter-to-quarter production volume, fixed production costs and related overhead absorption, raw ingredient costs, inventory mark to market write-downs and timing of shipments to customers.
Diagnostic services costs for the three months ended September 30, 2024 were zero compared to $0.1 million for the three months ended September 30, 2023. The decrease in diagnostic service costs of $0.1 million for the three months ended September 30, 2024 as compared to the three months ended September 30, 2023 was due to decreased COVID-19 testing volumes in 2024 compared to the 2023 period.
General and administration expenses for the three months ended September 30, 2024 were $7.7 million as compared to $8.2 million for the three months ended September 30, 2023. The decrease in general and administration expenses of $0.6 million for the three months ended September 30, 2024 as compared to the three months ended September 30, 2023 was principally related to a decrease in personnel expenses and professional fees associated with our diagnostic services business.
Research and development costs for the three months ended September 30, 2024 were $122,000 as compared to $428,000 for the three months ended September 30, 2023. The decrease in research and development costs of $306,000 for the three months ended September 30, 2024 as compared to the three months ended September 30, 2023 was principally due to decreased activities related to product research and field testing as a result of refined focus and efforts.
As a result of the effects described above, net loss for the three months ended September 30, 2024 was $6.6 million, or $(0.35) per share, as compared to net loss of $5.1 million, or $(0.30) per share, for the three months ended September 30, 2023. Diluted loss per share for the three months ended September 30, 2024 and 2023 were $(0.35) per share and $(0.30) per share, respectively.
Our aggregate cash and cash equivalents as of September 30, 2024 were $1.1 million as compared to $2.1 million at December 31, 2023. Our working capital was $13.5 million and $26.7 million as of September 30, 2024 and December 31, 2023, respectively. The decrease of $1.1 million in our cash and cash equivalents for the nine months ended September 30, 2024 was principally due to $14.0 million cash used in operating activities, capital expenditures of $1.1 million, and repayment of notes payable for $2,508,000, offset by proceeds from the sale of marketable debt securities of $3.4 million, proceeds from issuance of common stock, notes payable and mortgage loan of $13.0 million.
Conference Call Details:
To participate in the virtual conference call on November 13, 2024, at 11:00 AM ET, please register at:
About ProPhase Labs
ProPhase Labs, Inc. (Nasdaq: PRPH) is a next-generation biotech, genomics and diagnostics company. Our goal is to create a healthier world with bold action and the power of insight. We believe we are revolutionizing healthcare with industry-leading Whole Genome Sequencing solutions, while developing potential game changer diagnostics and therapeutics in the fight against cancer. This includes a potentially life-saving cancer test focused on early detection of esophageal cancer and potential breakthrough cancer therapeutics with novel mechanisms of action. Our world-class CLIA labs and cutting-edge diagnostic technology provide wellness solutions for healthcare providers and consumers. We develop, manufacture, and commercialize health and wellness solutions to enable people to live their best lives. We are committed to executional excellence, smart diversification, and a synergistic, omni-channel approach. ProPhase Labs’ subsidiaries and their strategic synergies highlight our potential for long-term value.
For more information, visit www.ProPhaseLabs.com
Forward Looking Statements
This press release contains “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “plan” or the negative of these terms and similar expressions intended to identify forward-looking statements. These statements include statements related to our strategy, plans, objectives and initiatives, including our expectations regarding the future revenue growth potential of each of our subsidiaries, the projected value of a sale of PMI, our expectations relating to PMI’s existing and new contracts, production, revenue, and earnings, the anticipated timing for the installation of additional lozenge lines and their ability to increase capacity and revenue, our expectation of potential and significant reductions in overhead and expenses before year-end, our expectations regarding outcomes of strategic discussions with healthcare consultants, advisors, and partners for BE-Smart, the success of the commercialization plan for BE-Smart, our expectations of revenue and earnings from a partnership for BE-Smart, our ability to enter into new domestic and international long-term contracts for our DNA Complete business and the financial impact of any such contracts, our anticipated expenses, ability to obtain funding for our operations and the sufficiency of our cash resources, and the expected timeline for completion of final statistical analysis of our Equivir clinical trial. The Company cautions readers that forward-looking statements are based on management’s expectations and assumptions as of the date of this release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including, but not limited to, risks related to prevailing market conditions, the impact of general economic, industry or political conditions in the United States, and the Company’s ability to satisfy customary closing conditions associated with the offering. Management believes that these forward-looking statements are reasonable as and when made. The Company undertakes no obligation to update forward-looking statements except as required by applicable securities laws.
Media Relations and Institutional Investor Contact:
ProPhase Labs, Inc.
267-880-1111
investorrelations@prophaselabs.com
Retail Investor Relations Contact:
Renmark Financial Communications
John Boidman
212-812-7680
Jboidman@renmarkfinancial.com
ProPhase Labs, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(in thousands, except share and per share amounts)
| September 30, 2024 | December 31, 2023 | |||||||
| (Unaudited) | ||||||||
| ASSETS | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 501 | $ | 1,609 | ||||
| Restricted cash | 593 | 540 | ||||||
| Marketable securities, available for sale | 2 | 3,127 | ||||||
| Accounts receivable, net | 31,638 | 36,313 | ||||||
| Inventory, net | 3,966 | 3,841 | ||||||
| Prepaid expenses and other current assets | 5,535 | 2,155 | ||||||
| Total current assets | 42,235 | 47,585 | ||||||
| Property, plant and equipment, net | 13,851 | 12,898 | ||||||
| Prepaid expenses, net of current portion | 431 | 832 | ||||||
| Operating lease right-of-use asset, net | 4,234 | 4,572 | ||||||
| Intangible assets, net | 10,396 | 12,333 | ||||||
| Goodwill | 5,231 | 5,231 | ||||||
| Deferred tax asset | 14,576 | 7,313 | ||||||
| Other assets | 854 | 1,163 | ||||||
| TOTAL ASSETS | $ | 91,808 | $ | 91,927 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | 15,459 | $ | 9,383 | ||||
| Accrued diagnostic services | 38 | 314 | ||||||
| Accrued advertising and other allowances | 122 | 24 | ||||||
| Finance lease liabilities | 3,897 | 1,840 | ||||||
| Operating lease liabilities | 971 | 953 | ||||||
| Short-term loan payable, net of discount of $758 | 2,670 | — | ||||||
| Deferred revenue | 1,647 | 2,382 | ||||||
| Income tax payable | 2,274 | 3,278 | ||||||
| Other current liabilities | 1,620 | 2,683 | ||||||
| Total current liabilities | 28,698 | 20,857 | ||||||
| Non-current liabilities: | ||||||||
| Secured long-term debt, net of discount of $324 and $341 | 2,925 | 2,924 | ||||||
| Unsecured promissory notes, net of discount of $142 and $266 | 9,858 | 7,334 | ||||||
| Due to sellers (see Note 3) | 2,000 | 2,000 | ||||||
| Deferred revenue, net of current portion | 928 | 1,100 | ||||||
| Operating lease liabilities, net of current portion | 3,663 | 4,237 | ||||||
| Finance lease liabilities, net of current portion | 3,885 | 4,092 | ||||||
| Total non-current liabilities | 24,984 | 21,687 | ||||||
| Total liabilities | 53,682 | 42,544 | ||||||
| COMMITMENTS AND CONTINGENCIES | ||||||||
| Stockholders’ equity | ||||||||
| Preferred stock authorized 1,000,000, $0.0005 par value, no shares issued and outstanding | — | — | ||||||
| Common stock authorized 50,000,000, $0.0005 par value, 19,078,529 and 18,045,029 shares outstanding, respectively | 18 | 18 | ||||||
| Additional paid-in capital | 126,339 | 118,694 | ||||||
| Accumulated deficit | (24,034 | ) | (5,029 | ) | ||||
| Treasury stock, at cost, 18,940,967 and 18,940,967 shares, respectively | (64,000 | ) | (64,000 | ) | ||||
| Accumulated other comprehensive loss | (197 | ) | (300 | ) | ||||
| Total stockholders’ equity | 38,126 | 49,383 | ||||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | 91,808 | $ | 91,927 | ||||
ProPhase Labs, Inc. and Subsidiaries
Condensed Consolidated Statements of Operations and Other Comprehensive Loss
(in thousands, except per share amounts)
(unaudited)
| For the three months ended | For the nine months ended | |||||||||||||||
| September 30, 2024 | September 30, 2023 | September 30, 2024 | September 30, 2023 | |||||||||||||
| Revenues, net | $ | 3,146 | $ | 8,365 | $ | 9,254 | $ | 40,885 | ||||||||
| Cost of revenues | 3,311 | 6,038 | 10,328 | 21,590 | ||||||||||||
| Gross (loss) profit | (165 | ) | 2,327 | (1,074 | ) | 19,295 | ||||||||||
| Operating expenses: | ||||||||||||||||
| Diagnostic expenses | — | 132 | — | 1,932 | ||||||||||||
| General and administration | 7,650 | 8,245 | 22,455 | 26,480 | ||||||||||||
| Research and development | 122 | 428 | 533 | 1,144 | ||||||||||||
| Total operating expenses | 7,772 | 8,805 | 22,988 | 29,556 | ||||||||||||
| Loss from operations | (7,937 | ) | (6,478 | ) | (24,062 | ) | (10,261 | ) | ||||||||
| Interest income, net | — | 1 | — | 39 | ||||||||||||
| Interest expense | (1,158 | ) | (275 | ) | (2,316 | ) | (781 | ) | ||||||||
| Other (expense) income | — | (33 | ) | 12 | (132 | ) | ||||||||||
| Loss from operations before income taxes | (9,095 | ) | (6,785 | ) | (26,366 | ) | (11,135 | ) | ||||||||
| Income tax benefit | 2,508 | 1,644 | 7,361 | 3,104 | ||||||||||||
| Loss from operations after income taxes | (6,587 | ) | (5,141 | ) | (19,005 | ) | (8,031 | ) | ||||||||
| Net loss | $ | (6,587 | ) | $ | (5,141 | ) | $ | (19,005 | ) | $ | (8,031 | ) | ||||
| Other comprehensive income (loss): | ||||||||||||||||
| Unrealized gain (loss) on marketable securities | 1 | (2,032 | ) | 103 | (2,201 | ) | ||||||||||
| Total comprehensive loss | $ | (6,586 | ) | $ | (7,173 | ) | $ | (18,902 | ) | $ | (10,232 | ) | ||||
| Loss per share: | ||||||||||||||||
| Basic | $ | (0.35 | ) | $ | (0.30 | ) | $ | (1.02 | ) | $ | (0.47 | ) | ||||
| Diluted | $ | (0.35 | ) | $ | (0.30 | ) | $ | (1.02 | ) | $ | (0.47 | ) | ||||
| Weighted average common shares outstanding: | ||||||||||||||||
| Basic | 19,079 | 17,175 | 18,672 | 16,924 | ||||||||||||
| Diluted | 19,079 | 17,175 | 18,672 | 16,924 | ||||||||||||
ProPhase Labs, Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows
(in thousands)
(unaudited)
| For the nine months ended | ||||||||
| September 30, 2024 | September 30, 2023 | |||||||
| Cash flows from operating activities | ||||||||
| Net loss | $ | (19,005 | ) | $ | (8,031 | ) | ||
| Adjustments to reconcile net loss to net cash (used in) provided by operating activities: | ||||||||
| Realized loss on marketable debt securities | 18 | (3 | ) | |||||
| Depreciation and amortization | 5,693 | 4,435 | ||||||
| Amortization of debt discount | 1,000 | 97 | ||||||
| Amortization on operating lease right-of-use assets | 338 | 325 | ||||||
| Stock-based compensation expense | 3,021 | 2,860 | ||||||
| Accounts receivable allowances | — | 718 | ||||||
| Credit loss expense, direct write-off | — | 74 | ||||||
| Inventory reserve | 21 | — | ||||||
| Gain from disposal of fixed assets | (91 | ) | — | |||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | 4,675 | (2,380 | ) | |||||
| Inventory | (146 | ) | (1,078 | ) | ||||
| Prepaid expenses and other current assets | (4,218 | ) | (938 | ) | ||||
| Deferred tax asset | (7,427 | ) | (4,350 | ) | ||||
| Other assets | 853 | — | ||||||
| Accounts payable and accrued expenses | 6,069 | (438 | ) | |||||
| Accrued diagnostic services | (276 | ) | (768 | ) | ||||
| Accrued advertising and other allowances | 98 | 14 | ||||||
| Deferred revenue | (907 | ) | (315 | ) | ||||
| Deferred tax liability | — | (307 | ) | |||||
| Operating lease liabilities | (1,710 | ) | (139 | ) | ||||
| Income tax payable | (1,004 | ) | (881 | ) | ||||
| Other liabilities | (969 | ) | (30 | ) | ||||
| Net cash used in operating activities | (13,967 | ) | (11,135 | ) | ||||
| Cash flows from investing activities | ||||||||
| Business acquisitions, escrow received | — | 478 | ||||||
| Asset acquisitions, net of cash acquired | — | (2,904 | ) | |||||
| Purchase of marketable securities | — | (3,819 | ) | |||||
| Proceeds from maturities of marketable securities | — | 4,168 | ||||||
| Proceeds from sales of marketable securities | 3,374 | 3,817 | ||||||
| Proceeds from sales of fixed assets | 229 | — | ||||||
| Capital expenditures | (1,141 | ) | (1,845 | ) | ||||
| Net cash provided by (used in) investing activities | 2,462 | (105 | ) | |||||
| Cash flows from financing activities | ||||||||
| Proceeds from issuance of note payable, net | 8,334 | 7,600 | ||||||
| Proceeds from issuance of common shares, net | 4,624 | — | ||||||
| Repurchases of common shares | — | (588 | ) | |||||
| Repurchase of common stock for payment of statutory taxes due on cashless exercise of stock option | — | (5,379 | ) | |||||
| Repayment of note payable | (2,508 | ) | — | |||||
| Net cash provided by financing activities | 10,450 | 2,833 | ||||||
| Decrease in cash, cash equivalents and restricted cash | (1,055 | ) | (8,407 | ) | ||||
| Cash, cash equivalents and restricted cash at the beginning of the period | 2,149 | 9,109 | ||||||
| Cash, cash equivalents and restricted cash at the end of the period | $ | 1,094 | $ | 702 | ||||
| Supplemental disclosures: | ||||||||
| Cash paid for income taxes | $ | 860 | $ | 3,000 | ||||
| Interest payment on the promissory notes | $ | 2,126 | $ | 740 | ||||
| Supplemental disclosure of non-cash investing and financing activities: | ||||||||
| Stock-based compensation included in the prepaid expense | $ | — | $ | 1,138 | ||||
| Net unrealized loss, investments in marketable debt securities | $ | 267 | $ | 2,083 | ||||
| Assets obtained in exchange for new finance lease obligations | $ | 3,699 | $ | 6,201 | ||||
| Reclassification between prepaid expenses and other assets | $ | 544 | $ | — | ||||
| Accrued offering cost | $ | 22 | $ | — | ||||
| Issuance of warrants with unsecured promissory note | $ | — | $ | 398 | ||||
| Common stock issued in asset acquisition | $ | — | $ | 1,000 | ||||
Non-GAAP Financial Measures and Reconciliation
In an effort to provide investors with additional information regarding our results of operations as determined by accounting principles generally accepted in the United States of America (“GAAP”), we disclose certain non-GAAP financial measures. The primary non-GAAP financial measures we disclose are EBITDA and Adjusted EBITDA.
We define “EBITDA” as net income (loss) before net interest expense, income taxes, depreciation and amortization. Adjusted EBITDA further adjusts EBITDA by excluding acquisition costs, other non-cash items, and other unusual or non-recurring charges (as described in the table below).
Non-GAAP financial measures should not be considered as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. These non-GAAP financial measures do not reflect a comprehensive system of accounting, differ from GAAP measures with the same names and may differ from non-GAAP financial measures with the same or similar names that are used by other companies. We compute non-GAAP financial measures using the same consistent method from quarter to quarter and year to year. We may consider whether other significant items that arise in the future should be excluded from the non-GAAP financial measures.
We use EBITDA and Adjusted EBITDA internally to evaluate and manage the Company’s operations because we believe they provide useful supplemental information regarding the Company’s ongoing economic performance. We believe that these non-GAAP financial measures provide meaningful supplemental information regarding our operating results primarily because they exclude amounts that are not considered part of ongoing operating results when planning and forecasting and when assessing the performance of the organization. In addition, we believe that non-GAAP financial information is used by analysts and others in the investment community to analyze our historical results and in providing estimates of future performance and that failure to report these non-GAAP measures could result in confusion among analysts and others and create a misplaced perception that our results have underperformed or exceeded expectations.
The following table sets forth the reconciliations of EBITDA and Adjusted EBITDA excluding other costs to the most comparable GAAP financial measures (in thousands):
| For the three months ended | For the nine months ended | ||||||||||||||
| September 30, 2024 | September 30, 2023 | September 30, 2024 | September 30, 2023 | ||||||||||||
| GAAP net income (1) | $ | (6,587 | ) | $ | (5,141 | ) | $ | (19,005 | ) | $ | (5,141) | ||||
| Interest, net | 1,158 | 274 | 2,316 | 274 | |||||||||||
| Income tax benefit | (2,508 | ) | (1,644 | ) | (7,361 | ) | (1,644) | ||||||||
| Depreciation and amortization | 2,390 | 3,143 | 5,693 | 3,143 | |||||||||||
| EBITDA | (5,547 | ) | (3,368 | ) | (18,357 | ) | (3,368) | ||||||||
| Share-based compensation expense | 636 | 744 | 3,021 | 744 | |||||||||||
| Non-cash rent expense (2) | 471 | 99 | 236 | 99 | |||||||||||
| Credit loss expense | — | — | — | — | |||||||||||
| Adjusted EBITDA | $ | (4,440 | ) | $ | (2,525 | ) | $ | (15,100 | ) | $ | (2,525) | ||||
(1) We believe that net income (loss) is the financial measure calculated and presented in accordance with GAAP that is most directly comparable to EBITDA and Adjusted EBITDA. EBITDA and Adjusted EBITDA measure the Company’s operating performance without regard to certain expenses. EBITDA and Adjusted EBITDA are not presentations made in accordance with GAAP and the Company’s computation of EBITDA and Adjusted EBITDA may vary from others in the industry. EBITDA and Adjusted EBITDA have important limitations as analytical tools and should not be considered in isolation or as substitutes for analysis of the Company’s results as reported under GAAP.
(2) The non-cash portion of rent, which reflects the extent to which our GAAP rent expense recognized exceeds (or is less than) our cash rent payments. For newer leases, our rent expense recognized typically exceeds our cash rent payments, while for more mature leases, rent expense recognized is typically less than our cash rent payments.
